DBV Technologies S.A. (NASDAQ:DBVT) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday.

Other equities research analysts have also recently issued reports about the company. Zacks Investment Research upgraded DBV Technologies from a “sell” rating to a “hold” rating and set a $49.00 price target on the stock in a research report on Tuesday, August 1st. ValuEngine cut DBV Technologies from a “hold” rating to a “sell” rating in a research report on Friday, June 30th. Morgan Stanley reiterated an “overweight” rating on shares of DBV Technologies in a research report on Monday, July 10th. Jefferies Group LLC reiterated a “buy” rating and set a $47.00 price target on shares of DBV Technologies in a research report on Thursday, June 1st. Finally, Deutsche Bank AG assumed coverage on DBV Technologies in a research report on Friday, June 23rd. They set a “buy” rating and a $46.00 price target on the stock. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. DBV Technologies has an average rating of “Buy” and an average target price of $48.83.

DBV Technologies (DBVT) traded down 0.37% during trading on Friday, reaching $43.02. 64,908 shares of the company were exchanged. The firm’s 50 day moving average price is $40.78 and its 200-day moving average price is $36.09. The stock’s market capitalization is $1.98 billion. DBV Technologies has a one year low of $31.87 and a one year high of $46.33.

COPYRIGHT VIOLATION NOTICE: “DBV Technologies S.A. (NASDAQ:DBVT) Downgraded by BidaskClub” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at https://www.watchlistnews.com/dbv-technologies-s-a-nasdaqdbvt-downgraded-by-bidaskclub/1472399.html.

Several large investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. boosted its position in DBV Technologies by 3.1% in the first quarter. Goldman Sachs Group Inc. now owns 55,499 shares of the company’s stock valued at $1,955,000 after buying an additional 1,647 shares during the period. Alps Advisors Inc. boosted its position in DBV Technologies by 4.9% in the second quarter. Alps Advisors Inc. now owns 43,513 shares of the company’s stock valued at $1,554,000 after buying an additional 2,040 shares during the period. Parametric Portfolio Associates LLC boosted its position in DBV Technologies by 9.2% in the first quarter. Parametric Portfolio Associates LLC now owns 33,270 shares of the company’s stock valued at $1,172,000 after buying an additional 2,794 shares during the period. Jennison Associates LLC boosted its position in DBV Technologies by 0.7% in the first quarter. Jennison Associates LLC now owns 537,726 shares of the company’s stock valued at $18,939,000 after buying an additional 3,577 shares during the period. Finally, Emory University boosted its position in DBV Technologies by 7.9% in the first quarter. Emory University now owns 62,884 shares of the company’s stock valued at $2,215,000 after buying an additional 4,628 shares during the period. Hedge funds and other institutional investors own 47.98% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with Analyst Ratings Network's FREE daily email newsletter.